CIP
ALXN

Chartwell Investment Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Chartwell Investment Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-9,240
Closed -$1.13M – 450
2016
Q4 		$1.13M Sell
9,240
-95,265
-91% -$11.7M 0.04% 367
2016
Q3 		$12.8M Buy
+104,505
New +$13.5M 0.23% 139
2014
Q4 		– Sell
-50,560
Closed -$8.38M – 382
2014
Q3 		$8.38M Sell
50,560
-58,150
-53% -$9.55M 0.19% 206
2014
Q2 		$17M Buy
108,710
+48,725
+81% +$7.69M 0.35% 109
2014
Q1 		$9.13M Buy
59,985
+920
+2% +$146K 0.19% 194
2013
Q4 		$7.85M Sell
59,065
-77,460
-57% -$9.3M 0.16% 215
2013
Q3 		$15.9M Sell
136,525
-2,425
-2% -$266K 0.36% 110
2013
Q2 		$12.8M Buy
+138,950
New +$13.4M 0.33% 130

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return